Get access

Surfactant for pulmonary haemorrhage in neonates

  • Review
  • Intervention


  • Abdul Aziz,

    1. William Osler Health Centre, Department of Pediatrics, Brampton, Ontario, Canada
    Search for more papers by this author
  • Arne Ohlsson

    Corresponding author
    1. University of Toronto, Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada
    • Arne Ohlsson, Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation, University of Toronto, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada.

    Search for more papers by this author



In the 1960s and 1970s, pulmonary haemorrhage (PH) occurred mainly in full-term infants with pre-existing illness with an incidence of 1.3 per 1000 live births. Risk factors for PH included severity of illness, intrauterine growth restriction, patent ductus arteriosus (PDA), coagulopathy and the need for assisted ventilation. Presently, PH occurs in 3% to 5% of preterm ventilated infants with severe respiratory distress syndrome (RDS) who often have a PDA and have received surfactant. The cause of PH is thought to be due to rapid lowering of intrapulmonary pressure, which facilitates left to right shunting across a PDA and an increase in pulmonary blood flow. Retrospective case reports and one prospective uncontrolled study have shown promising results for surfactant in treating PH.


To evaluate the effect of surfactant treatment compared to placebo or no intervention on mortality and morbidities in neonates with PH.

Search methods

For this update The Cochrane Library, Issue 2, 2012; MEDLINE; EMBASE; CINAHL;;; proceedings (2000 to 2011) of the Annual Meetings of the Pediatric Academic Societies (Abstracts2View) and Web of Science were searched on 8 February 2012.

Selection criteria

Randomised or quasi-randomised controlled trials that evaluated the effect of surfactant in the treatment of PH in intubated term or preterm (< 37 weeks) neonates with PH. Infants were included up to 44 weeks' postmenstrual age. The interventions studied were intratracheal instillation of surfactant (natural or synthetic, regardless of dose) versus placebo or no intervention.

Data collection and analysis

If studies were identified by the literature search, the planned analyses included risk ratio, risk difference, number needed to treat to benefit or to harm for dichotomous outcomes, and mean difference for continuous outcomes, with their 95% confidence intervals. A fixed-effect model would be used for meta-analyses. The risk of bias for included trials would be assessed. Heterogeneity tests, including the I2 statistic, would be performed to assess the appropriateness of pooling the data and the results would be reported.

Main results

No trials were identified.

Authors' conclusions

No randomised or quasi-randomised trials that evaluated the effect of surfactant in PH were identified. Therefore, no conclusions from such trials can be drawn. In view of the promising results from studies with less strict study designs than a randomised controlled trial, there is reason to conduct further trials of surfactant for the treatment of PH in neonates.








今回の更新では、コクラン・ライブラリ2012年第2号、MEDLINE、EMBASE、CINAHL、、、Annual Meetings of the Pediatric Academic Societies (Abstracts2View)の抄録(2000~2011年)、Web of Scienceを2012年2月8日に検索した。









Plain language summary

Surfactant for pulmonary haemorrhage in neonates

Bleeding into the lungs (pulmonary haemorrhage) occurs mainly in infants born before term (37 weeks' gestation) because of severe lung disease (particularly respiratory distress syndrome, a disease caused by the lack of the normal lining chemicals of the lung (surfactant)) and the need for a breathing machine (assisted ventilation). The risk factors for pulmonary haemorrhage include preterm birth, poor growth while in the womb (intrauterine growth restriction), respiratory problems, abnormal blood flow around the blood vessels in the lungs (patent ductus arteriosus), bleeding problems (coagulopathy), the need for a breathing machine and surfactant treatment. The underlining cause of pulmonary haemorrhage is thought to be a rapid increase in pulmonary blood flow due to a patent ductus arteriosus. Some studies have shown promising results with the use of surfactant treatment in infants with pulmonary haemorrhage. However, no randomised controlled trials were identified in this review. Currently, no recommendation for clinical practice based on randomised controlled trials can be presented; further research is needed.





監  訳: 江藤 宏美,2012.11.14

実施組織: 厚生労働省委託事業によりMindsが実施した。

ご注意 : この日本語訳は、臨床医、疫学研究者などによる翻訳のチェックを受けて公開していますが、訳語の間違いなどお気づきの点がございましたら、Minds事務局までご連絡ください。Mindsでは最新版の日本語訳を掲載するよう努めておりますが、編集作業に伴うタイム・ラグが生じている場合もあります。ご利用に際しては、最新版(英語版)の内容をご確認ください。

Ringkasan bahasa mudah

Surfaktan untuk neonat yang menghidapi hemoraj pulmonari

Perdarahan ke dalam paru-paru (hemoraj pulmonari) biasanya berlaku pada bayi yang dilahirkan sebelum cukup bulan (gestasi 37 minggu) akibat penyakit paru-paru yang teruk (terutama sindrom distres respiratori, suatu penyakit yang disebabkan kekurangan bahan-bahan kimia yang melapisi paru-paru (surfaktan)) dan keperluan menggunakan mesin membantu pernafasan (bantuan ventilasi). Faktor-faktor risiko untuk hemoraj pulmonari merangkumi kelahiran pramatang, pertumbuhan perlahan semasa dalam rahim (pertumbuhan intrauterine terhad), masalah pernafasan, aliran darah abnormal mengelilingi salur darah dalam paru-paru (duktus arteriosus paten), masalah perdarahan (coagulopathy), keperluan menggunakan mesin membantu pernafasan dan rawatan surfaktan. Punca asas hemoraj pulmonari dianggap berkait dengan pertambahan aliran darah pulmonari disebabkan duktus arteriosus paten. Beberapa kajian telah menunjukkan keputusan yang menyakinkan dengan kegunaan rawatan surfaktan dalam bayi dengan hemoraj pulmonari. Bagaimanapun, tiada kajian rawak terkawal dikenalpasti dalam ulasan ini. Pada masa ini, tiada cadangan untuk amali klinikal berdasarkan kajian rawak terkawal dapat dikemukakan; kajian tambahan diperlukan.

Catatan terjemahan

Diterjemahkan oleh Foo Sook Lee.(Penang Medical College) Untuk sebarang pertanyaan berkaitan terjemahan ini sila hubungi Disunting oleh Tan May Loong (Penang Medical College)